Common coupling map advances GPCR-G protein selectivity
- University of Copenhagen, Denmark
- University of Montreal, Canada
- Domain Therapeutics North America, Canada
- Tohoku University, Japan
Abstract
Two-thirds of human hormones and one-third of clinical drugs act on membrane receptors that couple to G proteins to achieve appropriate functional responses. While G protein transducers from literature are annotated in the Guide to Pharmacology database, two recent large-scale datasets now expand the receptor-G protein 'couplome'. However, these three datasets differ in scope and reported G protein couplings giving different coverage and conclusions on GPCR-G protein signaling. Here, we report a common coupling map uncovering novel couplings supported by both large-scale studies, the selectivity/promiscuity of GPCRs and G proteins, and how the co-coupling and co-expression of G proteins compare to the families from phylogenetic relationships. The coupling map and insights on GPCR-G protein selectivity will catalyze advances in receptor research and cellular signaling towards the exploitation of G protein signaling bias in design of safer drugs.
Data availability
All underlying data are available in Spreadsheets S1-5. The obtained common coupling map is available in the online database GproteinDb at https://gproteindb.org/signprot/couplings.
-
Quantitative G protein and B-arrestin profiles of 100 therapeutically relevant GPCRsbioRxiv https://www.biorxiv.org/.
-
Quantitative G protein profiles of 150 GPCRsCell https://www.cell.com/.
-
Qualitative G protein profiles of 254 GPCRsNucleic Acids Research https://academic.oup.com/nar.
Article and author information
Author details
Alexander Sebastian Hauser
Funding
Canadian Institutes of Health Research (FDN-148431)
- Michel Bouvier
Lundbeckfonden (R218-2016-1266)
- David E Gloriam
Lundbeckfonden (R313-2019-526)
- David E Gloriam
Novo Nordisk Fonden (NNF18OC0031226)
- David E Gloriam
Basis for Supporting Innovative Drug Discovery and Life Science Research (JP20am0101095)
- Asuka Inoue
Leading Asia's Private Infrastructure Fund (JP20gm0010004)
- Asuka Inoue
Japan Agency for Medical Research and Development
- Asuka Inoue
Takeda Science Foundation
- Asuka Inoue
Uehara Memorial Foundation
- Asuka Inoue
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2022, Hauser et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 5,140
- views
-
- 915
- downloads
-
- 80
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Common coupling map advances GPCR-G protein selectivity
eLife 11:e74107.
https://doi.org/10.7554/eLife.74107
Further reading
-
- Cancer Biology
- Computational and Systems Biology
This study investigates the variability among patients with non-small cell lung cancer (NSCLC) in their responses to immune checkpoint inhibitors (ICIs). Recognizing that patients with advanced-stage NSCLC rarely qualify for surgical interventions, it becomes crucial to identify biomarkers that influence responses to ICI therapy. We conducted an analysis of single-cell transcriptomes from 33 lung cancer biopsy samples, with a particular focus on 14 core samples taken before the initiation of palliative ICI treatment. Our objective was to link tumor and immune cell profiles with patient responses to ICI. We discovered that ICI non-responders exhibited a higher presence of CD4+ regulatory T cells, resident memory T cells, and TH17 cells. This contrasts with the diverse activated CD8+ T cells found in responders. Furthermore, tumor cells in non-responders frequently showed heightened transcriptional activity in the NF-kB and STAT3 pathways, suggesting a potential inherent resistance to ICI therapy. Through the integration of immune cell profiles and tumor molecular signatures, we achieved an discriminative power (area under the curve [AUC]) exceeding 95% in identifying patient responses to ICI treatment. These results underscore the crucial importance of the interplay between tumor and immune microenvironment, including within metastatic sites, in affecting the effectiveness of ICIs in NSCLC.
-
- Computational and Systems Biology
- Developmental Biology
Understanding the principles underlying the design of robust, yet flexible patterning systems is a key problem in developmental biology. In the Drosophila wing, Hedgehog (Hh) signaling determines patterning outputs using dynamical properties of the Hh gradient. In particular, the pattern of collier (col) is established by the steady-state Hh gradient, whereas the pattern of decapentaplegic (dpp), is established by a transient gradient of Hh known as the Hh overshoot. Here we use mathematical modeling to suggest that this dynamical interpretation of the Hh gradient results in specific robustness and precision properties. For instance, the location of the anterior border of col, which is subject to self-enhanced ligand degradation is more robustly specified than that of dpp to changes in morphogen dosage, and we provide experimental evidence of this prediction. However, the anterior border of dpp expression pattern, which is established by the overshoot gradient is much more precise to what would be expected by the steady-state gradient. Therefore, the dynamical interpretation of Hh signaling offers tradeoffs between
